<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org).">
  <meta name="generator" content="bookdown 0.0.79 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="github-repo" content="shanmdphd/PAPER" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-07-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="session-1-rare-diseases-in-korea-status-research-experiences.html">
<link rel="next" href="session-3-lessons-and-learned-rd-for-rare-disease.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>2</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="2.1" data-path="opening-remark.html"><a href="opening-remark.html"><i class="fa fa-check"></i><b>2.1</b> Opening Remark</a></li>
<li class="chapter" data-level="2.2" data-path="first-session.html"><a href="first-session.html"><i class="fa fa-check"></i><b>2.2</b> First Session</a><ul>
<li class="chapter" data-level="2.2.1" data-path="first-session.html"><a href="first-session.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>2.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="2.2.2" data-path="first-session.html"><a href="first-session.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>2.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="2.2.3" data-path="first-session.html"><a href="first-session.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>2.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="second-session.html"><a href="second-session.html"><i class="fa fa-check"></i><b>2.3</b> Second Session</a><ul>
<li class="chapter" data-level="2.3.1" data-path="second-session.html"><a href="second-session.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>2.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="2.3.2" data-path="second-session.html"><a href="second-session.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>2.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="2.3.3" data-path="second-session.html"><a href="second-session.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>2.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="2.3.4" data-path="second-session.html"><a href="second-session.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>2.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>3</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="3.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html"><i class="fa fa-check"></i><b>3.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="3.1.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-1--------"><i class="fa fa-check"></i><b>3.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="3.1.2" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-2----"><i class="fa fa-check"></i><b>3.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html"><i class="fa fa-check"></i><b>3.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="3.2.1" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>3.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="3.2.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>3.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="3.2.3" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-3-------"><i class="fa fa-check"></i><b>3.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>4</b> ACREP</a><ul>
<li class="chapter" data-level="4.1" data-path="observational-study.html"><a href="observational-study.html"><i class="fa fa-check"></i><b>4.1</b> Observational Study</a><ul>
<li class="chapter" data-level="4.1.1" data-path="observational-study.html"><a href="observational-study.html#contents"><i class="fa fa-check"></i><b>4.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html"><i class="fa fa-check"></i><b>4.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="4.2.1" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-yes"><i class="fa fa-check"></i><b>4.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="4.2.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-no"><i class="fa fa-check"></i><b>4.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="4.2.3" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#contents-1"><i class="fa fa-check"></i><b>4.2.3</b> Contents</a></li>
<li class="chapter" data-level="4.2.4" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#conclusion"><i class="fa fa-check"></i><b>4.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html"><i class="fa fa-check"></i><b>4.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="4.3.1" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>4.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="4.3.2" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---biomarker"><i class="fa fa-check"></i><b>4.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="-.html"><a href="-.html"><i class="fa fa-check"></i><b>4.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="4.5" data-path="-clinical-prediction-model-individual-riskoutcome-probability-.html"><a href="-clinical-prediction-model-individual-riskoutcome-probability-.html"><i class="fa fa-check"></i><b>4.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="4.6" data-path="web-r-org.html"><a href="web-r-org.html"><i class="fa fa-check"></i><b>4.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="4.6.1" data-path="web-r-org.html"><a href="web-r-org.html#contents-2"><i class="fa fa-check"></i><b>4.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="prism.html"><a href="prism.html"><i class="fa fa-check"></i><b>5</b> Prism</a><ul>
<li class="chapter" data-level="5.1" data-path="morning.html"><a href="morning.html"><i class="fa fa-check"></i><b>5.1</b> Morning</a><ul>
<li class="chapter" data-level="5.1.1" data-path="morning.html"><a href="morning.html#lim-covariate-model"><i class="fa fa-check"></i><b>5.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="5.1.2" data-path="morning.html"><a href="morning.html#fda---lee"><i class="fa fa-check"></i><b>5.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="5.1.3" data-path="morning.html"><a href="morning.html#pfizer"><i class="fa fa-check"></i><b>5.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html"><i class="fa fa-check"></i><b>5.2</b> PRISM Afternoon</a><ul>
<li class="chapter" data-level="5.2.1" data-path="prism-afternoon.html"><a href="prism-afternoon.html#kim"><i class="fa fa-check"></i><b>5.2.1</b> Kim</a></li>
<li class="chapter" data-level="5.2.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>5.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="5.2.3" data-path="prism-afternoon.html"><a href="prism-afternoon.html#mbdd"><i class="fa fa-check"></i><b>5.2.3</b> MBDD</a></li>
<li class="chapter" data-level="5.2.4" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>5.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="5.2.5" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>5.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><a href="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><i class="fa fa-check"></i><b>6</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="6.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html"><i class="fa fa-check"></i><b>6.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="6.1.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>6.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="6.1.2" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>6.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><i class="fa fa-check"></i><b>6.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="6.2.1" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>6.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="6.2.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>6.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="session-3-lessons-and-learned-rd-for-rare-disease.html"><a href="session-3-lessons-and-learned-rd-for-rare-disease.html"><i class="fa fa-check"></i><b>6.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a></li>
<li class="chapter" data-level="6.4" data-path="session-4-asan-initia-tives-for-rare-disease.html"><a href="session-4-asan-initia-tives-for-rare-disease.html"><i class="fa fa-check"></i><b>6.4</b> Session 4 Asan initia tives for rare disease</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="session-2-global-regulatory-experiences-in-orphan-drug-development" class="section level2">
<h2><span class="header-section-number">6.2</span> Session 2 Global regulatory experiences in orphan drug development</h2>
<div id="considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism" class="section level3">
<h3><span class="header-section-number">6.2.1</span> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</h3>
<p>Speaker: In Sook Kim, Ph.D. FDA Office of Clinical Pharmacology</p>
<ul>
<li>Beginning with the goal in mind</li>
<li>45 NME/New BLA in 2015</li>
<li>Novel Drug Approval for rare diseases 2010-2015, 77 novel drugs for rare (37 cancer, 10 inborn e of metabolism)</li>
<li>Rare disease (Orphan disease) - less than 200k</li>
<li>~500 rare disease have approved drugs. / ~7000 rare disease</li>
<li>Goals: safe and efficacious drug</li>
<li>uncertainty를 줄이고, evidence of efficacy and safety</li>
<li>Challenging: Limited clinical experiences, Lakc of understanding of natural history of the disease - limited opportunities for learning</li>
<li>Ivacaftor: CFTR protein - for G551D(Defective CFTR protein), hard to apply <img src="http://www.cftr.info/wp-content/uploads/m1_s2_03_02_01_tab2_v2.jpg" /></li>
<li><a href="http://investors.vrtx.com/releasedetail.cfm?ReleaseID=902790">Phase II Trial</a></li>
<li>Phase 2 Trial - 39 patients</li>
<li>PD parameters: sweat Cl, Nose potential difference, Lung function: FEV1</li>
<li><a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1409547">NEJM</a></li>
<li>Eliglustat (<a href="http://www.cerdelga.com/">Cerdelga<sup>®</sup></a>)</li>
<li>glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test</li>
<li>Metabolized by CYP2D6, CYP3A4</li>
<li>Simulation and Modeling</li>
<li>EM, systemic exposure at SS is 7-9 fold higher in poor metabolizer</li>
<li>PBPK analysis - CYP2D6, CYP3A4 inhibitor 동시에 넣었을때 24배 증가 prediction</li>
<li>Contraindication!</li>
<li>Risk management에서 중요함!</li>
<li>Sebelipase alfa (<a href="http://www.kanuma.com/">Kanuma<sup>®</sup></a>)</li>
<li>2 Pivotal studies (Infantile-onset(Wolman ds), Late-onset(Cholesteryl ester storage ds))</li>
<li>FDA-APPROVED TREATMENT FOR LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D)</li>
<li>Webpage<a href="#fn1" class="footnoteRef" id="fnref1"><sup>1</sup></a></li>
<li>Opportunities for innovation</li>
</ul>
</div>
<div id="role-of-pharmacometrics-in-the-development-of-orphan-drugs" class="section level3">
<h3><span class="header-section-number">6.2.2</span> Role of pharmacometrics in the development of orphan drugs</h3>
<p>14:10 ~ 14:35 (’25) Speaker: Jee Eun Lee, Ph.D. FDA</p>
<p>14:35 ~ 14:45 (’10) Q &amp; A 14:45 ~ 15:00 (’15) Break</p>
</div>
</div>
<div class="footnotes">
<hr />
<ol start="1">
<li id="fn1"><p><a href="http://news.alexionpharma.com/press-release/product-news/fda-approves-kanuma-sebelipase-alfa-treatment-patients-lysosomal-acid-lip" class="uri">http://news.alexionpharma.com/press-release/product-news/fda-approves-kanuma-sebelipase-alfa-treatment-patients-lysosomal-acid-lip</a><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#fnref1">↩</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="session-1-rare-diseases-in-korea-status-research-experiences.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="session-3-lessons-and-learned-rd-for-rare-disease.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-07-14-MFDS.Rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
